|1.||Doroshenko, B H: 5 articles (04/2009 - 04/2003)|
|2.||Saxena, Renu: 4 articles (05/2015 - 03/2006)|
|3.||Saliuta, M Iu: 4 articles (04/2009 - 10/2007)|
|4.||Karpenko, O I: 4 articles (04/2009 - 10/2007)|
|5.||Bezuhlova, S V: 4 articles (04/2009 - 10/2007)|
|6.||Glueck, Charles J: 4 articles (07/2008 - 12/2002)|
|7.||Sun, Wei: 3 articles (12/2015 - 02/2006)|
|8.||Maehara, Yoshihiko: 3 articles (11/2014 - 02/2008)|
|9.||Shetty, Shrimati: 3 articles (09/2014 - 09/2004)|
|10.||Ghosh, Kanjaksha: 3 articles (09/2014 - 09/2004)|
|1.||Disseminated Intravascular Coagulation
06/01/1988 - "Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation."
01/01/1987 - "Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat."
08/01/2007 - "Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study."
12/01/2014 - "Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation."
12/01/2010 - "Assessment of the usefulness of antithrombin-III in the management of disseminated intravascular coagulation in obstetrically Ill patients."
01/01/1993 - "Therapy of the thrombosis may be improved with administration of antithrombin III concentrates."
09/01/1992 - "The administration of AT III concentrate caused an improvement in thrombosis. "
11/01/1989 - "[Efficacy of antithrombin-III in a case of portal thrombus]."
04/15/1995 - "Further studies are needed to evaluate whether the therapeutically-induced normalization of AT III levels can reduce the thrombosis degree."
01/01/1988 - " These researchers claim that in both this and earlier studies, changes in AT-III levels were rarely in a range associated with a risk factor for thrombosis. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1995 - " For example, studies have established a relationship between oral contraceptive use and changes in antithrombin III. A case is presented which highlights the multifaceted nature of venous thromboses and the need for clinicians to be aware of potential hypercoagulable states and their implications for patient care. "
07/03/2014 - "Using zinc finger nucleases, we show that disruption of the zebrafish antithrombin III (at3) locus results in spontaneous venous thrombosis in larvae. "
10/01/2009 - "[Denaturing high-performance liquid chromatography for screening antithrombin III gene mutation and polymorphisms in patients with cerebral venous thrombosis]."
07/01/2006 - "Antithrombotic activity of Russian preparation Antithrombin III was studied on rat model of induced venous thrombosis. "
07/01/2006 - "Antithrombotic activity of Russian antithrombin III preparation on the model of induced venous thrombosis."
12/01/2008 - "Recent controlled studies that evaluated the efficacy of an adjuvant antithrombin (AT) III therapy in severe sepsis used a uniform AT-III dose and duration of therapy and did not adjust to the actual AT-III deficit. "
12/01/2008 - "It was the aim of the present study to explore if surgical patients with severe sepsis might have a treatment benefit from an activity-guided AT-III therapy. "
02/01/2006 - "To explore if patients with severe sepsis and with a predicted high risk of death (according to the Simplified Acute Physiology Score II) might have a treatment benefit from high-dose antithrombin III. Subgroup analysis of a randomized, placebo-controlled, double-blind, prospective phase III study. "
08/01/2002 - "Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]."
03/01/2001 - "In animal studies the prophylactic treatment with AT III in a dose > 250 U/kg prevented the development of disseminated intravascular coagulopathy and vital organ dysfunction during sepsis and lowered the mortality rate. "
01/01/2000 - "In conclusion, during the AT III substitution, no bleeding, no clinical side effects but improvement in multiple organ dysfunction including increase in platelet count was recorded."
01/01/2003 - "This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants. "
01/01/1997 - "In our study we tried to show the effect of early AT-III substitution on coagulation parameters and the incidence of intraventricular hemorrhage (IVH). "
03/01/1993 - "Antithrombin III activity increased from 0.26 +/- 0.04 SE U/ml to 0.82 +/- 0.07 U/ml at 3 h post infusion (normal range 0.80-1.20 U/ml) and remained greater than 0.80 U/ml throughout the study without any apparent increase in the frequency of bleeding. "
12/01/2013 - "Clinically, recombinant human antithrombin III attenuated the increased pulmonary transvascular fluid flux (12-48 hr: p ≤ 0.001 vs control each) and the deteriorated pulmonary gas exchange (12-48 hr: p < 0.05 vs control each) without increasing the risk of bleeding. "
|5.||Fibrinogen (Factor I)
|7.||fibrin fragment D (D-dimer)
|9.||Plasminogen Activators (Plasminogen Activator)
|10.||Factor VII (Proconvertin)
|1.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|3.||Hip Replacement Arthroplasty (Total Hip Replacement)
|4.||Cardiopulmonary Bypass (Heart-Lung Bypass)